Anastrozole is an oral non-selective aromatase inhibitor approved for adjuvant treatment of early-stage, hormone receptor-positive breast cancer in postmenopausal women. It also reduces plasma estrogen levels by inhibiting aromatase. This drug also has some common side effects such as hot flashes, altered mood, joint pain, and nausea.
Key Drivers and Restraints of Global Anastrozole Tablets Market
Prevalence of postmenopausal breast cancer has increased globally. In 2018, the age-standardized incident rates per 100,000 was 19.7 cases of premenopausal and 152.6 cases of postmenopausal breast cancer. The highest premenopausal breast cancer age-standardized incident rates was in Western Europe (38.4 per 100,000). Breast cancer is the most frequent cancer among women, affecting 2.1 million women each year and causes the largest number of cancer-related deaths among women. In 2018, an estimated 627,000 women died of breast cancer i.e., nearly 15% of all cancer deaths among women. Hence, rise in cases of various diseases fuels market growth.
Product launch is also boosting market revenue. In July 2020, Aurobindo Pharma Limited received the U.S. FDA approval for Anastrozole Tablets USP, 1 mg. In September 2019, Cooper Pharma launched ANAZBOL (anastrozole tablets) in New Delhi, India, to treat breast cancer in women who have gone through menopause.
However, frequent product recalls is likely to restrain the global market. In July 2019, Cadila Healthcare recalled its Anastrozole tablets. This recall was issued due to GMP deviations and potential cross-contamination due to cleaning procedure failure. In April 2019, Zydus recalled anastrozole due to a GMP cleaning procedure failure in the Fluid Bed Dryer Processor area. This recall was initiated in support of the recall by the manufacturer, Zydus, dated May 3, 2019, which included lots that were repackaged by American Health Packaging.
